Meropenem Kabi

Meropenem Trihydrate, the active ingredient in Meropenem Kabi, is a carbapenem antibiotic presented as a sterile powder for intravenous use. It is employed to treat severe bacterial infections, including intra‑abdominal, urinary, respiratory, central nervous system infections, and sepsis, in hospitalized adult patients.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our global distribution network ensures timely delivery and compliance with local regulatory requirements. We maintain rigorous quality control to guarantee product integrity.

Meropenem Kabi is a carbapenem antibiotic used to treat serious bacterial infections across several organ systems. - Complicated intra‑abdominal infections: achieves bacterial eradication in the peritoneal cavity, reducing infection‑related morbidity. - Complicated urinary tract infections: provides effective coverage against resistant Gram‑negative and Gram‑positive uropathogens. - Hospital‑acquired pneumonia: combats multidrug‑resistant organisms causing lower respiratory tract infection in hospitalized patients. - Ventilator‑associated pneumonia: delivers rapid bactericidal activity in intubated patients with ventilator‑related lung infection. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis caused by susceptible strains. - Severe sepsis and septic shock: supports systemic infection control in critically ill patients with septic physiology.

Meropenem Kabi may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: mild to moderate watery stools. - Nausea: occasional feeling of queasiness. - Vomiting: transient emesis. - Injection site pain: discomfort at the intravenous infusion site. - Elevated liver enzymes: transient increase in ALT/AST. - Headache: mild headache episodes.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Severe allergic reactions: anaphylaxis, rash, or angioedema. - Clostridioides difficile colitis: antibiotic‑associated intestinal infection. - Hemolytic anemia: rare immune‑mediated red cell destruction. - Thrombocytopenia: low platelet count leading to bleeding risk.

When using Meropenem Kabi, clinicians should consider several precautionary measures to ensure safe administration. - Renal function: adjust dose in patients with impaired kidney function to avoid accumulation. - Hypersensitivity: avoid in individuals with known allergy to carbapenems or other β‑lactams. - CNS disorders: monitor for neurotoxicity, especially seizures, in patients with pre‑existing CNS disease. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Concomitant nephrotoxic drugs: exercise caution when combined with other renal‑toxic agents. - Store at below 25°C: keep in original container, protect from moisture and light.